Welcome to our dedicated page for Novocure SEC filings (Ticker: NVCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Scanning Novocure’s latest 300-page disclosures for clinical-trial milestones or reimbursement updates can feel overwhelming. Oncology device filings must track FDA feedback, global patient enrollments, and complex royalty agreements—details buried deep inside a single annual report 10-K. If you came here after searching "Novocure SEC filings explained simply" or "How do I track Novocure insider trading Form 4 transactions?", you’re in the right place.
Stock Titan’s platform turns each dense document into plain-language insight. Our AI produces side-by-side summaries so you can move from Novocure quarterly earnings report 10-Q filing headlines to full cash-flow tables in one click. Real-time alerts surface Novocure Form 4 insider transactions real-time, letting you monitor executive sentiment before data readouts. Need a quick brief? Try "understanding Novocure SEC documents with AI"—our engine highlights segment revenue shifts, TTFields adoption metrics, and litigation updates without the jargon.
Whether you’re analyzing a sudden Novocure 8-K material events explained notice, comparing option grants inside the Novocure proxy statement executive compensation, or scanning Novocure executive stock transactions Form 4, every filing is indexed, searchable, and updated the moment it hits EDGAR. Practical use cases include:
- Flagging device-sales momentum through Novocure earnings report filing analysis
- Spotting insider buying patterns ahead of pivotal trial updates
- Cross-checking R&D spend trends with previous periods
No more piecing together spreadsheets or waiting for secondary sources; our AI delivers a Novocure annual report 10-K simplified experience built for portfolio managers, sell-side analysts, and diligent retail investors alike.
NovoCure Ltd. (NVCR) reported an insider transaction on Form 4 for its Chief Financial Officer. On 11/04/2025, 7,033 ordinary shares were withheld at $12.23 to satisfy tax obligations from the vesting of Restricted Stock Units. Following this withholding (transaction code F), the CFO directly holds 134,117 shares. The filing notes the action was not discretionary and was approved pursuant to Rules 16b-3(e) and 16b-3(d)(1).
NovoCure Ltd. (NVCR) reported insider activity by Chief Operating Officer Mukund Paravasthu related to RSU vesting tax withholding. On 11/01/2025, the issuer withheld 168 ordinary shares at $12.81 per share. On 11/04/2025, the issuer withheld an additional 2,949 ordinary shares at $12.23 per share. These are coded “F” transactions, reflecting shares withheld to satisfy tax obligations and described as non-discretionary. Following these transactions, Paravasthu directly beneficially owned 80,439 ordinary shares.
NovoCure Ltd (NVCR) reported an insider transaction on a Form 4. The company’s officer, EVP, President, Novocure Oncology, had 966 ordinary shares withheld on 11/01/2025 at $12.81 per share to satisfy tax obligations upon the vesting of Restricted Stock Units (transaction code F).
Following this non-discretionary withholding, the officer beneficially owns 347,745 shares, held directly. The filing indicates it was made by one reporting person.
NovoCure Ltd (NVCR): The company’s Chief Human Resources Officer reported a tax withholding transaction tied to RSU vesting. On 10/31/2025, 752 ordinary shares were withheld under Transaction Code F at $12.82 per share to satisfy withholding obligations. Following the transaction, the officer beneficially owns 163,762 shares, held directly. The filing notes the action was non‑discretionary and approved pursuant to Rules 16b‑3(e) and 16b‑3(d)(1).
NovoCure Limited (NVCR) reported third-quarter 2025 results showing continued top-line growth alongside operating losses. Net revenues were $167,204 (thousands), up 8% year over year, driven by growth in France, Germany and other international markets, partially offset by lower U.S. prior-period claim benefits and $3,300 of FX tailwinds. Gross margin was 73% versus 77% a year ago, reflecting higher array costs, tariffs, and a $2,900 inventory obsolescence charge for Optune Lua arrays.
The company recorded a net loss of $37,270 (thousands) and operating loss of $36,021 (thousands). Cash and cash equivalents were $342,119 with short-term investments of $691,382 as of September 30, 2025. NovoCure drew the Tranche B term loan, bringing its senior secured credit facility borrowings to $200,000, and its 0% Convertible Senior Notes due 2025 carried a current liability of $560,620.
Commercial metrics improved: active patients rose to 4,416 from 4,113, and total prescriptions increased to 1,805 from 1,586. Management highlighted clinical and regulatory milestones, including PANOVA-3 results and ongoing PMA filings for pancreatic cancer (Optune Pax) and brain metastases from NSCLC (Optune Mya), while noting a potential impact from a U.S. government shutdown on FDA and reimbursement timelines.
NovoCure Limited reported that it issued a press release announcing certain financial results for the quarter ended June 30, 2025. The announcement was furnished in an 8-K dated October 30, 2025.
The press release is provided as Exhibit 99.1.
NovoCure (NVCR) insider purchase by CEO Ashley Cordova: The filing reports that on 09/05/2025 the reporting person purchased 81,550 ordinary shares in multiple trades at prices ranging from $12.02 to $12.47, with a weighted average price of $12.2239. After the purchases, the reporting person beneficially owned 437,569 shares. The Form 4 identifies Ashley Cordova as Chief Executive Officer and a director, and the filing was signed by an attorney-in-fact on 09/08/2025. The filer notes willingness to provide detailed trade-level prices and quantities on request.
Capital World Investors (CWI) reports beneficial ownership of 6,382,848 shares of NovoCure Ltd. common stock, representing 5.7% of the 111,485,634 shares believed outstanding. CWI is identified as an investment adviser division of Capital Research and Management Company and related entities that provide investment management services under the name "Capital World Investors." The filing states CWI has sole voting and sole dispositive power over all 6,382,848 shares and that the holdings are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
FAQ
What is the current stock price of Novocure (NVCR)?
What is the market cap of Novocure (NVCR)?
